Finding. CASIN, the CDC42 inhibitor that previously put aged alpha-synuclein oligomer mice back on their feet, now has a brain-wide transcriptional receipt. Single-nucleus RNA-seq across 6, 16, and 24 months says the Parkinson-related programs are most reversibly written at 24 months, while aging programs scream loudest at 16. The downstream maps are MAPK and PI3K/AKT. The authors’ synthesis is an EGFR–PI3K–MAPK axis through which CDC42 blockade may restore mitochondrial and synaptic function. That last clause is an inference, and it is why this paper is on a mitochondrial desk.
Why this paper matters
This model already made a sharp claim: oligomers are not enough. You need the aging milieu, and CDC42 sits in that milieu. A motor rescue without a map is a curiosity. A rescue with an age-stratified snRNA-seq atlas is a parts list.
The mitochondrial sentence is doing honest work and needs to be read as such. MAPK and PI3K/AKT are real mitochondrial-adjacent programs (biogenesis, FOXO, synaptic ATP). The paper does not show that mitochondria or synapses were restored in this dataset. It shows the transcriptional routes that would make that restoration plausible.
What they actually measured
Inducible alpha-synuclein oligomer mice, three ages, four conditions (OFF/ON × CASIN), both sexes, 3–4 mice each. 10x 3-prime snRNA-seq from one hemisphere, 0 to −5 mm Bregma. Network and pathway analysis. Result geometry: CASIN reverts PD-related alterations most clearly at 24 months; aging-related changes are strongest at 16 months. Mode of action: MAPK and PI3K/AKT in aging; MAPK in PD. Nominated axis: EGFR, PI3K, MAPK.
The title promises cell-type-specific transcriptomes and MAPK-driven transcription-factor networks. The abstract is more age-and-pathway than a named dopaminergic-versus-GABAergic table. Believe the title when the cell-type supplements appear.
How to read the score
Low seventies as a mitochondrial brief, mid seventies as a PD-aging transcriptomics brief. Confidence is medium. Score 72. Do not upgrade it to an OXPHOS rescue paper.
What to do with it
Track if you model aging × α-synuclein, CDC42, or MAPK/PI3K in brain mitochondria. Pull the 24-month versus 16-month cell-type tables and ask which mitochondrial genes actually move. Do not treat CASIN or EGFR inhibitors as PD therapy from this brief. The directional implication is that an age-hyperactive CDC42 program writes MAPK/PI3K networks that sit over mitochondria and synapses, and that those networks remain chemically writable late.